Smith Stevens S, Fiore Michael C, Baker Timothy B
Department of Medicine, University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, WI, USA; Center for Tobacco Research and Intervention, UWSMPH, Madison, WI, USA.
Addiction. 2014 Dec;109(12):2107-17. doi: 10.1111/add.12661. Epub 2014 Jul 21.
To assess the relations of menthol cigarette use with measures of cessation success in a large comparative effectiveness trial (CET).
Participants were randomized to one of six medication treatment conditions in a randomized double-blind, placebo-controlled clinical trial. All participants received six individual counseling sessions.
Community-based smokers in two communities in Wisconsin, USA.
A total of 1504 adult smokers who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. The analysis sample comprised 1439 participants: 814 white non-menthol smokers, 439 white menthol smokers and 186 African American (AA) menthol smokers. There were too few AA non-menthol smokers (n = 16) to be included in the analyses.
Nicotine lozenge, nicotine patch, bupropion sustained release, nicotine patch + nicotine lozenge, bupropion + nicotine lozenge and placebo.
Biochemically confirmed 7-day point-prevalence abstinence assessed at 4, 8 and 26 weeks post-quit.
In longitudinal abstinence analyses (generalized estimating equations) controlling for cessation treatment, menthol smoking was associated with reduced likelihood of smoking cessation success relative to non-menthol smoking [model-based estimates of abstinence = 31 versus 38%, respectively; odds ratio (OR) = 0.71, 95% confidence interval (CI) = 0.59, 0.86]. In addition, among menthol smokers, AA women were at especially high risk of cessation failure relative to white women (estimated abstinence = 17 versus 35%, respectively; OR = 2.63, 95% CI = 1.75, 3.96; estimated abstinence rates for AA males and white males were both 30%, OR = 1.06, 95% CI = 0.60, 1.66).
In the United States, smoking menthol cigarettes appears to be associated with reduced cessation success compared with non-menthol smoking, especially in African American females.
在一项大型比较疗效试验（CET）中评估薄荷醇香烟使用与戒烟成功指标之间的关系。
在一项随机双盲、安慰剂对照临床试验中，参与者被随机分配到六种药物治疗条件之一。所有参与者均接受六次个体咨询。
美国威斯康星州两个社区的社区吸烟者。
共有1504名成年吸烟者，他们在过去6个月中每天至少吸10支烟，并表示有戒烟意愿。分析样本包括1439名参与者：814名白人非薄荷醇吸烟者、439名白人薄荷醇吸烟者和186名非裔美国人（AA）薄荷醇吸烟者。AA非薄荷醇吸烟者太少（n = 16），未纳入分析。
尼古丁含片、尼古丁贴片、安非他酮缓释片、尼古丁贴片 + 尼古丁含片、安非他酮 + 尼古丁含片和安慰剂。
在戒烟后4周、8周和26周评估经生化确认的7天点患病率戒断情况。
在控制戒烟治疗的纵向戒断分析（广义估计方程）中，与非薄荷醇吸烟相比，吸薄荷醇香烟与戒烟成功可能性降低相关[基于模型的戒断估计值分别为31%和38%；优势比（OR） = 0.71，95%置信区间（CI） = 0.59，0.86]。此外，在薄荷醇吸烟者中，与白人女性相比，AA女性戒烟失败的风险尤其高（估计戒断率分别为17%和35%；OR = 2.63，95%CI = 1.75，3.96；AA男性和白人男性的估计戒断率均为30%，OR = 1.06，95%CI = 0.60，1.66）。
在美国，与非薄荷醇吸烟相比，吸薄荷醇香烟似乎与戒烟成功率降低有关，尤其是在非裔美国女性中。
